How Initiatives like our Academies are a Solution to the CRA Staffing Crisis Many professionals within the Clinical Research community are already aware of the current issues plaguing the industry, not just within the UK but on a global scale. During the last quarter of 2016 CNN Money ranked CRAs as one of the 10
In recognition of International Clinical Trials day, Clinical Professionals invites Deborah Bruce, Training Academy Manager, to provide some personal insight and reflect on the importance of clinical trials. As today is International Clinical Trials Day, which marks the anniversary of the first clinical trial by James Lind in 1747, I find myself reflecting on my
Cellectis, a French biopharmaceutical firm, has entered into a translational research collaboration with Weill Cornell Medical College situated in the US. The alliance will aim to fast-track development of a targeted immunotherapy for patients with acute myelogenous leukaemia (AML). The partnership will be combining Cellectis’ work in the development and manufacture of gene edited CAR
Four Scottish health boards have partnered up with Pfizer to become the organisation’s second INSPIRE site within the UK, aimed at driving clinical research. The four health boards are NHS Grampian, Greater Glasgow & Clyde, Lothian and Tayside. The health boards have already heavily invested in the research endeavour through NHS Research Scotland (NRS), a
GlaxoSmithKline and Johnson & Johnson (J&J) announced yesterday that they have started Phase III clinical trials of their investigational rheumatoid arthritis (RA) treatment, sirukumab. Johnson & Johnson’s Janssen Biologics unit in Ireland and GlaxoSmithKline have begun a Phase III development programme for sirukumab (otherwise known as CNTO 136), a human anti-interleukin (IL)-6 monoclonal antibody. The
Experts from the University of Southampton are to start research to discover whether stress can cause dementia. The study, which is being financed by the Alzheimer’s Society, will observe 140 people who currently have mild cognitive impairment or “pre-dementia” and investigate how stress affects the condition. They hope that the study will expose methods to
Parexel yesterday announced that they have extended their alliance network for early-phase research by partnering with University Hospitals Bristol National Health Service Foundation Trust (UH Bristol), which is one of the UK’s biggest specialist training and research hospital trusts. With this arrangement Parexel continues to increase their network, which complements the US-based biopharmaceutical services company’s
